Best practices for identifying men who have sex with men for corrections-based pre-exposure prophylaxis provision

by Lauren Brinkley-Rubinstein, Meghan Peterson, Nickolas D. Zaller, David A. Wohl
Published 2019-04-01

Estimated Impact of Targeted Pre-Exposure Prophylaxis: Strategies for Men Who Have Sex with Men in the United States

by Richard A. Elion, Mina Kabiri, Kenneth H. Mayer, David A. Wohl, Joshua Cohen, Anne C. Beaubrun, Frederick L. Altice
Published 2019-05-01

Does HAART efficacy translate to effectiveness? Evidence for a trial effect.

by Prema Menezes, William C Miller, David A Wohl, Adaora A Adimora, Peter A Leone, William C Miller, Joseph J Eron
Published 2011-01-01

Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy.

by Andrea S Foulkes, David A Wohl, Ian Frank, Elaine Puleo, Stephanie Restine, Megan L Wolfe, Michael P Dube, Pablo Tebas, Muredach P Reilly
Published 2006-03-01

Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial.

by David A Wohl, Laveeza Bhatti, Catherine B Small, Howard Edelstein, Henry H Zhao, David A Margolis, Edwin DeJesus, Winkler G Weinberg, Lisa L Ross, Mark S Shaefer
Published 2014-01-01

The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit.

by David A Wohl, Michelle A Kendall, Judith Feinberg, Beverly Alston-Smith, Susan Owens, Suzette Chafey, Michael Marco, Sharon Maxwell, Constance Benson, Philip Keiser, Charles van der Horst, Mark A Jacobson, A5030 Study Team
Published 2013-01-01